| Document and Entity Information - Jun. 30, 2015 - shares | Total |
| Document And Entity Information [Abstract] | |
| Document Type | 10-Q |
| Amendment Flag | false |
| Document Period End Date | Jun. 30, 2015 |
| Entity Registrant Name | Fona, Inc. |
| Entity Central Index Key | 884,363 |
| Current Fiscal Year End Date | --12-31 |
| Document Fiscal Period Focus | Q2 |
| Document Fiscal Year Focus | 2,015 |
| Entity Filer Category | Smaller Reporting Company |
| Entity Common Stock, Shares Outstanding | 7,894,111 |
| BALANCE SHEETS - USD ($) | Jun. 30, 2015 | Dec. 31, 2014 |
| Current Assets: | ||
| Cash | ||
| Prepaid Expenses | $ 7,500 | |
| Total Current Assets | 7,500 | |
| TOTAL ASSETS | $ 7,500 | |
| Current Liabilities: | ||
| Accounts payable | ||
| Accounts payable, related party | $ 36,135 | $ 13,672 |
| Total Current Liabilities | 36,135 | 13,672 |
| TOTAL LIABILITIES | $ 36,135 | $ 13,672 |
| Commitments and contingencies (Notes 1, 2, 4 and 5) | ||
| Stockholders' (Deficit) | ||
| Preferred Stock, $.001 par value 20,000,000 shares authorized; No shares issued and outstanding | ||
| Common stock, $.001 par value 780,000,000 shares authorized, 7,894,111 issued and outstanding (Note 4) | $ 7,894 | $ 7,894 |
| Additional paid-in capital | 1,312,323 | 1,312,323 |
| Accumulated (Deficit) | (1,348,852) | (1,333,889) |
| TOTAL STOCKHOLDERS' EQUITY OR (DEFICIT) | (28,635) | $ (13,672) |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY OR (DEFICIT) | $ 7,500 |
| BALANCE SHEETS (Parenthetical) - $ / shares | Jun. 30, 2015 | Dec. 31, 2014 |
| Statement of Financial Position [Abstract] | ||
| Preferred stock, par value | $ 0.001 | $ 0.001 |
| Preferred stock, authorized shares | 20,000,000 | 20,000,000 |
| Preferred stock, issued shares | 0 | 0 |
| Preferred stock, outstanding shares | 0 | 0 |
| Common stock, par value | $ 0.001 | $ 0.001 |
| Common stock, authorized shares | 780,000,000 | 780,000,000 |
| Common stock, issued shares | 7,894,111 | 7,894,111 |
| Common stock, outstanding shares | 7,894,111 | 7,894,111 |
| STATEMENTS OF OPERATIONS - USD ($) None in scaling factor is -9223372036854775296 | 3 Months Ended | 6 Months Ended | ||
| Jun. 30, 2015 | Jun. 30, 2014 | Jun. 30, 2015 | Jun. 30, 2014 | |
| Income Statement [Abstract] | ||||
| Revenue | ||||
| Expenses: | ||||
| Accounting and audit fees | $ 3,810 | $ 5,200 | $ 9,610 | $ 5,200 |
| Attorney fees | 1,614 | 1,614 | ||
| Transfer agent fees | $ 150 | 550 | $ 450 | 915 |
| Filing Fees | $ 972 | $ 1,611 | $ 2,403 | 1,611 |
| General corporate fees | $ 750 | |||
| Exchange fees | $ 2,500 | $ 2,500 | ||
| Other | $ 5 | $ 10 | ||
| Total Expenses | $ 7,432 | 8,980 | $ 14,963 | 10,100 |
| Net Operating (Loss) | $ (7,432) | (8,980) | $ (14,963) | (10,100) |
| Other Expenses: | ||||
| Interest Expense | 1,346 | 2,636 | ||
| Total Other Expenses | 1,346 | 2,636 | ||
| Net Other (Expense) | (1,346) | (2,636) | ||
| Net (Loss) | $ (7,432) | $ (10,326) | $ (14,963) | $ (12,736) |
| Per Share | ||||
| Weighted Average Shares Outstanding | 7,894,111 | 7,894,111 | 7,894,111 | 7,894,111 |
| STATEMENTS OF CASH FLOWS - USD ($) | 6 Months Ended | |
| Jun. 30, 2015 | Jun. 30, 2014 | |
| Cash Flows from Operating Activities: | ||
| Net Income (Loss) | $ (14,963) | $ (12,736) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non cash interest | 2,636 | |
| (Decrease) in accounts payable and accrued expenses | (1,550) | |
| (Increase) Decrease in prepaid expenses | $ (7,500) | 150 |
| Net Cash (Used in) Operating Activities | $ (22,463) | $ (11,500) |
| Cash Flows from Investing Activities | ||
| Cash Flows from Financing Activities: | ||
| Advance from related party | $ 22,463 | $ 11,490 |
| Net Cash Provided by Financing Activities | $ 22,463 | 11,490 |
| Increase (decrease) in Cash | (10) | |
| Cash, Beginning of Period | 641 | |
| Cash, End of Period | $ 631 | |
| Interest Paid | ||
| Income Taxes Paid | ||
| Supplemental Disclosure of Non-Cash Transactions: | ||
| Conversion of debt to paid in capital | $ 88,002 | |
| Unaudited Financial Statements | 6 Months Ended |
| Jun. 30, 2015 | |
| Unaudited Financial Statements [Abstract] | |
| Unaudited Financial Statements | (1) Unaudited Financial Statements The balance sheet as of June 30, 2015, the statements of operations for the three months and six months ended June 30, 2015 and 2014 and the statements of cash flows for the six months ended June 30, 2015 and 2014 have been prepared by Fona, Inc. (the Company) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures, normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted as allowed by such rules and regulations, and the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and changes in financial position at June 30, 2015 and for all periods presented, have been made. It is suggested that these statements be read in conjunction with the December 31, 2014 audited financial statements and the accompanying notes included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission. |
| Basis of Presentation | 6 Months Ended |
| Jun. 30, 2015 | |
| Accounting Policies [Abstract] | |
| Basis of Presentation | (2) Basis of Presentation The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern. However, the Company has no active business operations and has negative working capital and stockholders deficits, which raise substantial doubt about its ability to continue as a going concern. In view of these matters, realization of certain of the assets in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to meet its financial requirements, raise additional capital, and the success of its future operations. The financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has previously financed its operations primarily through cash advances from related parties. A related party advanced the Company $22,463 during the six months ended June 30, 2015 and the balance due to that related party was $36,135 as of June 30, 2015. Management has opted to resume the filing of Securities and Exchange Commission (SEC) reporting documentation and then to seek a business combination. Management believes that this plan provides an opportunity for the Company to continue as a going concern. |
| Common Stock | 6 Months Ended |
| Jun. 30, 2015 | |
| Stockholders' Equity Note [Abstract] | |
| Common Stock | (3) Common Stock Pursuant to the Articles of Incorporation as amended, the Company is authorized to issue 780,000,000 common shares with $.001 par value. As of June 30, 2015, there were 7,894,111 shares of common stock issued and outstanding. |
| Related Party Transactions | 6 Months Ended |
| Jun. 30, 2015 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions | (4) Related Party Transactions For the six months ended June 30, 2015, Evolutionary Genomics, Inc., the majority shareholder of the Company as of June 30, 2015, advanced $22,463 in payment of expenses on behalf of the Company. The Company uses the offices of its President for its mailing address and minimal office facility needs for no consideration. No provision for these costs has been provided since it has been determined that they are immaterial. |
| Amended and Restated Agreement and Plan of Merger | 6 Months Ended |
| Jun. 30, 2015 | |
| Business Combinations [Abstract] | |
| Amended and Restated Agreement and Plan of Merger | (5) Amended and Restated Agreement and Plan of Merger On June 6, 2014, Evolutionary Genomics, EG I, Fona, Fona Merger Sub, Inc., and Fona Merger Sub, LLC entered into a merger agreement as amended by the Amended and Restated Agreement and Plan of Merger dated March 2, 2015, pursuant to which, subject to certain conditions, Fona Merger Sub, Inc. will merge with Evolutionary Genomics and Fona Merger Sub, LLC will merge with EG I, with each Evolutionary Genomics and EG I surviving as wholly-owned subsidiaries of Fona. Pursuant to the terms of the merger agreement, at the effective time of the Mergers, the Company shall cause to be paid or issued to stockholders of record of Evolutionary Genomics as of the effective time of the Mergers, 308,821,675 newly issued shares of Fonas common stock and 47,323,188 shares of newly issued Fona common stock to the members of EG I. The closing of the Mergers shall occur on or before December 31, 2015, unless earlier terminated. Evolutionary Genomics and EG I may at any time mutually agree to change the method of effecting the Mergers, including entering into an appropriate amendment to the merger agreement. The merger agreement contains customary representations and warranties of Evolutionary Genomics, EG I, Fona, and Fonas subsidiaries. The merger agreement also contains customary covenants and agreements, including, without limitation, covenants relating to the conduct of Fonas business between the date of signing of the merger agreement and closing date. Notwithstanding the limitations in the merger agreement, each of Evolutionary Genomics, EG I and Fona retain the right to engage in discussions or negotiations regarding alternative acquisition proposals to the extent necessary to fulfill the fiduciary duties of their respective boards of directors to their stockholders, subject to certain requirements. The Mergers are intended to be a transaction or transactions described in Section 351 of the Internal Revenue Code (the Code). The completion of the Mergers are subject to the satisfaction or waiver of certain closing conditions, including, without limitation, (i) the approval and adoption by the EG stockholders and EG I members of the merger agreement, (ii) the issuance of the Merger consideration in connection with the consummation of the Mergers, (iii) the effectiveness of a joint proxy statement/prospectus included in Fonas registration statement on Form S-4, (iv) holders of either securities in Evolutionary Genomics and EG I shall not be entitled to dissenters or appraisal rights, (v) absence of certain orders or regulations prohibiting the consummation of the Mergers, (vi) the effectiveness of a one-for-60.8826565 reverse split of the Common Stock (no fractional shares will be issued or cash in lieu of shares; fractional shares will be rounded up or down to the nearest whole number), and (vii) the approval or consent of any governmental authorities and third parties with respect to the transactions contemplated by the merger agreement. |
| Subsequent Events | 6 Months Ended |
| Jun. 30, 2015 | |
| Subsequent Events [Abstract] | |
| Subsequent Events | (6) Subsequent Events The Company has evaluated events subsequent to June 30, 2015 and through the date the financial statements were available to be issued, to assess the need for potential recognition or disclosure in this report. No events were noted that require recognition or disclosure in the financial statements. |
| Basis of Presentation (Policies) | 6 Months Ended |
| Jun. 30, 2015 | |
| Accounting Policies [Abstract] | |
| Basis of Presentation | The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern. However, the Company has no active business operations and has negative working capital and stockholders deficits, which raise substantial doubt about its ability to continue as a going concern. In view of these matters, realization of certain of the assets in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to meet its financial requirements, raise additional capital, and the success of its future operations. The financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has previously financed its operations primarily through cash advances from related parties. A related party advanced the Company $22,463 during the six months ended June 30, 2015 and the balance due to that related party was $36,135 as of June 30, 2015. Management has opted to resume the filing of Securities and Exchange Commission (SEC) reporting documentation and then to seek a business combination. Management believes that this plan provides an opportunity for the Company to continue as a going concern. |
| Basis of Presentation (Details) - USD ($) | 6 Months Ended | ||
| Jun. 30, 2015 | Jun. 30, 2014 | Dec. 31, 2014 | |
| Related Party Transaction [Line Items] | |||
| Cash advances from related party | $ 22,463 | $ 11,490 | |
| Accounts payable, related parties | 36,135 | $ 13,672 | |
| Evolutionary Genomics, Inc. [Member] | |||
| Related Party Transaction [Line Items] | |||
| Cash advances from related party | 22,463 | ||
| Accounts payable, related parties | $ 36,135 | ||
| Common Stock (Details) - $ / shares | Jun. 30, 2015 | Dec. 31, 2014 |
| Stockholders' Equity Note [Abstract] | ||
| Common stock, par value | $ 0.001 | $ 0.001 |
| Common stock, authorized shares | 780,000,000 | 780,000,000 |
| Common stock, issued shares | 7,894,111 | 7,894,111 |
| Common stock, outstanding shares | 7,894,111 | 7,894,111 |
| Related Party Transactions (Details) - USD ($) | 6 Months Ended | |
| Jun. 30, 2015 | Jun. 30, 2014 | |
| Related Party Transaction [Line Items] | ||
| Cash advances from related party | $ 22,463 | $ 11,490 |
| Evolutionary Genomics, Inc. [Member] | ||
| Related Party Transaction [Line Items] | ||
| Cash advances from related party | $ 22,463 | |
| Amended and Restated Agreement and Plan of Merger (Details) - 1 months ended Jun. 30, 2014 - shares | Total |
| Business Acquisition [Line Items] | |
| Date of agreement amendment | Mar. 2, 2015 |
| Maximum [Member] | Scenario, Forecast [Member] | |
| Business Acquisition [Line Items] | |
| Effective date of merger | Dec. 31, 2015 |
| Evolutionary Genomics, Inc. [Member] | Common Stock [Member] | Scenario, Forecast [Member] | |
| Business Acquisition [Line Items] | |
| Newly issued shares provided to shareholders pursuant to terms of Amended Merger Agreement | 308,821,675 |
| EG I, LLC [Member] | Common Stock [Member] | Scenario, Forecast [Member] | |
| Business Acquisition [Line Items] | |
| Newly issued shares provided to shareholders pursuant to terms of Amended Merger Agreement | 47,323,188 |
